Ramm Pharma Corp.’s Acquisition Of 49% Interest in Canapar Corp.

Ramm Pharma investe in Canapar rilevandone il 49%

Cassels Brock & Blackwell and Grimaldi Studio Legale have represented Ramm Pharma in the transaction. Ramm Pharma Corp., a leader in plant-derived cannabinoid (CBD) pharmaceutical and…

This content is for members only.
Login to Read More Join Now
Avatar

Author: Ambrogio Visconti

This content is for members only.
Login to Read More Join Now